diabetes glp-1 agonist New Guidelines for Type 2 in 2025 How GLP-1 medications are transforming

For example, both triple agonists retatrutide and HM15211 have shown promising results

Subsequently, reduced inflammation was achieved via administration of NLY01, a GLP-1RA, resulting in lower levels of RGC death and astrogliosis

I'm just bringing up, Hey, look, this is what the research is starting to point towards

Patients who received the maximum recommended dose of Mounjaro experienced substantial weight loss, with some individuals losing up to 21% of their body weight

31 Since there is significant residual CVD risk in patients with diabetes, even after accounting for traditional risk factors, the development of novel therapeutic avenues is needed to address it

Clinical studies have shown that these medications reduce glucose levels in people with diabetes without the problems of weight gain or risk of low glucose associated with some other diabetes treatments